Compartmentalisation of death receptor signalling in cancer
Abstract
Death Receptor (DR) ligands, such as CD95L and TRAIL, are historically considered as key players of tumour immunosurveillance through their ability to induce cell death. Yet, depending on the cellular context, their corresponding DR, CD95 and TRAILR1/2, also initiate various non-cytotoxic pathways and cellular functions and display multiple pro-tumoural functions across various cancer types. To unleash the full potential of the therapeutic targeting of DR signalling, it is therefore essential to understand the molecular mechanisms that tip the scales between their anti- and pro-tumoural effects. DR signalling is physiologically tightly regulated, and hence widely dysregulated in cancer, at multiple steps. Herein, focusing on the DR CD95, TRAILR1/2 and TNFR1, we first summarise their main signalling regulatory steps and therapeutic strategies developed for their targeting in cancer. Then, we focus on the emerging and sometimes controversial roles of cellular compartmentalisation in the regulation of DR signalling in cancer.
Related
- Diurnal and seasonal regulation of brain mu-opioid and dopamine D2 receptor signalling in humans
- Targeting microglial P2Y12-receptor signalling attenuates neurodegeneration in experimental Parkinsons disease
- C3a receptor signalling in ObRb-expressing neurons promotes leptin resistance and obesity-associated cardiac remodelling
- Atypical T cell receptor signalling permits distinct gut gd T cell responses to healthy versus dysregulated tissues
- The chemokine receptor‐like fourth extracellular loop of the apelin receptor differentially regulates apelin and elabela binding and signalling
BibTeX
@article{maltret2026compartmentalisation,
title = {{Compartmentalisation of death receptor signalling in cancer}},
author = {Victoria Maltret and Elodie Lafont},
journal = {Oncogenesis},
year = {2026},
month = sep,
doi = {10.1038/s41389-026-00654-w},
url = {https://hal.science/hal-05762967v1},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Compartmentalisation of death receptor signalling in cancer
AU - Victoria Maltret
AU - Elodie Lafont
PY - 2026
DA - 2026/09/24
JO - Oncogenesis
DO - 10.1038/s41389-026-00654-w
UR - https://hal.science/hal-05762967v1
AB - Death Receptor (DR) ligands, such as CD95L and TRAIL, are historically considered as key players of tumour immunosurveillance through their ability to induce cell death. Yet, depending on the cellular context, their corresponding DR, CD95 and TRAILR1/2, also initiate various non-cytotoxic pathways and cellular functions and display multiple pro-tumoural functions across various cancer types. To unleash the full potential of the therapeutic targeting of DR signalling, it is therefore essential to understand the molecular mechanisms that tip the scales between their anti- and pro-tumoural effects. DR signalling is physiologically tightly regulated, and hence widely dysregulated in cancer, at multiple steps. Herein, focusing on the DR CD95, TRAILR1/2 and TNFR1, we first summarise their main signalling regulatory steps and therapeutic strategies developed for their targeting in cancer. Then, we focus on the emerging and sometimes controversial roles of cellular compartmentalisation in the regulation of DR signalling in cancer.
SN - 2157-9024
SN - 2157-9024
ER -